News | May 27, 2025
Aurobindo Pharma Q4 PAT falls marginally to Rs. 903 Cr
During the quarter, US formulations revenue increased by 13.5 per cent YoY to Rs. 4,072 crore
During the quarter, US formulations revenue increased by 13.5 per cent YoY to Rs. 4,072 crore
Net profit for the?quarter came in at Rs. 2,889.1 crore, up 4.8 per cent from the year earlier, adjusted for exceptional items
Akums invested Rs. 272 crore in capital expenditure during FY25
YESINTEK is indicated for the treatment of adults and children from the age of 6 years and olde
R&D spend for Q4 was Rs. 50.3 crore, 4.9 per cent of Q4?revenue
Adjusted Profit After Tax (PAT) for the year ended March 31, 2025 was at Rs. 1,389.4 crore
Sun Pharma will invest up to $25 million in US-based Pharmazz Inc, raising its stake to 22.7%
Allopurinol is used to prevent or lower high uric acid levels in the blood
Merck KGaA, Darmstadt, Germany announced the presentation of new oncology data across more than 12 tumor types at ASCO 2025
Certification bolsters Venus Remedies' position in PIC/S markets, reinforcing commitment to global quality standards
Subscribe To Our Newsletter & Stay Updated
